3 Reasons Pfizer Stock Will Crush the Broader Market in 2022

3 Reasons Pfizer Stock Will Crush the Broader Market in 2022
·4 min read

Pfizer (NYSE: PFE) has been the second-best-performing big pharma stock for the whole of 2021. Pfizer's shares have soared this year due to its dominance in the COVID-19 vaccine market, as well as its late-stage trial success with the oral antiviral pill Paxlovid. Despite this sizable jump in 2021, Pfizer seems primed to crush the broader market yet again in 2022.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting